Mr. Trump is considering Jim O’Neill, a Silicon Valley investor, and Balaji Srinivasan, a former biotechnology industry executive, to head the FDA. Both candidates are associates of venture capitalist Peter Thiel, Mr. Trump’s science and technology adviser, and neither has a medical background. Mr. O’Neill is a proponent of granting FDA approval to drugs that are proven safe, even if their effectiveness has not yet been proven, according to the report.
“We’d want someone in that position who is knowledgeable about drug development or patient care,” Roger Perlmutter, MD, PhD, head of research and development at Merck & Co., said Jan. 9 in an interview with Bloomberg at the J.P. Morgan Healthcare Conference in San Francisco. Dr. Perlmutter said an ideal candidate is a physician scientist with experience in clinical care and medical research. “We wouldn’t want somebody in there who didn’t have that level of understanding, but they could come from a lot of different environments,” such as public health, he said.
Mr. Trump’s transition team did not respond to Bloomberg‘s requests for a comment on the matter.
More articles on supply chain:
FDA safety alert: LIFEPAK 1000 defibrillator shuts down unexpectedly during treatment
McKesson agrees to $150M settlement over reporting of painkiller orders
5 latest FDA approvals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.